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Abstract
Purpose The primary aim of this retrospective study was to describe the treatment patterns according to the type of treat-
ment received by patients with metastatic colorectal cancer (mCRC) in Spain.
Methods This was a retrospective, observational, multicenter study performed by 33 sites throughout Spain that included 
consecutive patients aged 18 years or older who had received or were receiving treatment for mCRC.
Results At the time of inclusion, of the 873 evaluable patients, 507 (58%) had received two lines, 235 (27%) had received 
three lines, 106 (12%) had received four lines, and the remaining patients had received up to ten lines. The most frequent 
chemotherapy schemes were the FOLFOX or CAPOX regimens (66%) for first-line treatment, FOLFOX, CAPOX or FOL-
FIRI (70%) for second-line treatment, and FOLFOX, FOLFIRI or other fluoropyrimidine-based regimens for third- and 
fourth-line (over 60%) treatment. Sixty percent of patients received targeted therapy as part of their first-line treatment, and 
this proportion increased up to approximately 70% of patients as part of the second-line of treatment. A relevant proportion 
of patients were treated with unknown KRAS, and especially the BRAF, mutation statuses.
Conclusions This study reveals inconsistencies regarding adherence to the recommendations of the ESMO guidelines for 
the management of mCRC in Spain. Improved adherence to the standard practice described in such guidelines for the deter-
mination of RAS and BRAF mutation statuses and the use of targeted therapies in first-line treatment should be considered 
to guarantee that patients can benefit from the best therapeutic approaches available.
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Introduction
Colorectal cancer (CRC) is a leading cause of cancer-
related morbidity and mortality worldwide, and its global 
burden is expected to increase in the coming years [1]. 
By the time of diagnosis, approximately 25% of patients 
exhibit metastatic disease, and almost 50% of patients will 
develop metastasis during the course of the disease [2]. 
Overall, the clinical outcome of metastatic (m) CRC has 
improved in the last decade, probably as a consequence of 
the availability of improved systemic treatment options 
and the improvements in the management of the disease 
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[3]. Management of mCRC should be guided by the avail-
able clinical practice guidelines (CPGs) [3, 4]. However, 
treatment patterns in patients with mCRC may vary from 
country to country [5] and even within the same coun-
try due to variations in practice and/or restrictions for 
the use of some drugs [6, 7]. In addition, adherence to 
the guidelines for managing CRC may also vary and has 
been reported as acceptable in some countries [6, 8] and 
suboptimal in others [7]. In a recent study conducted in 
the Netherlands, the treatment strategies agreed with the 
national guidelines in only two-thirds of the patients with 
stage II colon cancer, and targeted therapy was not rou-
tinely administered as first-line treatment in a substantial 
proportion of patients with mCRC [7]. In addition to the 
factors mentioned above, it has been reported that age, 
sex, ethnicity, type of residence and geographical region 
may affect access to KRAS mutation testing and that 
these disparities in access to mutation analysis could be 
responsible, at least in part, for a reduced adherence to the 
guidelines on this regard [9, 10]. Incomplete or unreliable 
tests in some laboratories could also affect adherence to 
biomarker testing guidelines [11].
Adherence to CPGs is of paramount interest because 
CPGs have the potential to reduce inappropriate practice 
variations, improve the translation of research evidence 
into clinical practice and improve the quality and safety 
of healthcare [12]. Adherence to CPGs has been associ-
ated with better treatment outcomes in patients with breast 
cancer [13], cervical cancer [14] and colorectal cancer 
[15, 16]. Information on treatment patterns for mCRC in 
Spain is limited to a study conducted with a private data-
base (LifeLink Oncology Analyzer Database) in France, 
Germany, Italy and Spain that included 649 patients from 
Spain, who were mostly patients of medical oncologists 
[5], and a single-center study that included 157 patients 
[17]. These studies provide some information on how 
mCRC is treated in Spain and different treatment patterns 
from those in other European countries, which could be 
explained by differences in local treatment guidelines, 
physician prescribing behaviors or reimbursement policies 
[5]; additionally, in accordance with other European stud-
ies, many laboratories were not ready for biomarker testing 
in the context of anti-EGFR therapy [17]. However, these 
studies did not evaluate whether the treatment patterns 
were consistent with the recommendations of the CPGs.
The primary aim of this retrospective study was to 
describe the treatment patterns according to the type of 
treatment received by patients with mCRC in Spain. The 
secondary objectives were to describe these patterns by 
ECOG performance status and KRAS mutation status and 
to describe the adherence of those treatment patterns to the 
ESMO and SEOM guidelines for the treatment of mCRC.
Patients and methods
The STREAM (Study on the TREAtment of Metastatic 
colorectal cancer) study was a retrospective, observational, 
multicenter study performed by 33 sites throughout Spain. 
The study was approved by a clinical research ethics com-
mittee. After being informed about the study, all patients 
gave their written informed consent before any study pro-
cedures were performed.
The study included consecutive patients aged 18 years 
or older who had received or were receiving treatment 
for mCRC before being enrolled in the study and who 
provided their written informed consent. Patients were 
excluded if they exhibited a cognitive impairment that 
precluded their understanding of the study characteristics, 
as they were described in the patient information sheet. 
The inclusion of patients participating in clinical trials 
was allowed.
The following information was collected by the inves-
tigators from the patients’ medical histories between the 
date of diagnosis and the day prior to signing the informed 
consent form: demographic and anthropometric data; data 
related to the initial diagnosis, including date, primary 
tumor location and clinical stage based on the TNM clas-
sification; diagnosis of metastatic disease, including date 
of diagnosis, location of metastases and clinical stage as 
per the TNM classification; KRAS/BRAF mutation status; 
ECOG performance status; and treatment for metastatic 
disease, including treatment line and scheme, start and end 
dates, reason for treatment discontinuation, best response 
and date of progression for each of the treatment lines 
received.
Based on data from a large cohort of patients with 
mCRC, it was estimated that 28% of patients with mCRC 
receive at least three lines of treatment [18], and thus this 
subgroup of patients could reflect the most frequent treat-
ment patterns. To obtain a proportion of patients with a 
precision of ± 3% and a 95% confidence interval, a total of 
844 patients were required; assuming that 5% of patients 
had missing data, it was calculated that a total of 889 
patients were required.
Continuous outcomes were described with the mean 
and standard deviation or with the median and interquar-
tile range when required. Categorical outcomes were 
described using the absolute and relative frequencies. 
To evaluate adherence to the clinical practice guidelines, 
we focused on the ESMO guidelines issued in 2012 [19], 
2014 [20] and 2016 [3]. The ranges of dates for each of 
these evaluations were 30-06-2010 to 04-09-2014 for 
adherence to ESMO 2012, 04-09-2014 to 08-07-2016 for 
adherence to ESMO 2014, and after 08-07-2016 for adher-
ence to ESMO 2016. A specific guideline was considered 
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applicable to a particular patient if the date of the diag-
nosis was within the above-mentioned range of dates. 
We considered that treatment that was not supported by 
the corresponding guidelines (e.g., gemcitabine) as non-
adherent to those regimens. Regarding KRAS/NRAS/BRAF 
mutation status, we considered that the patient was non-
adherent with all three ESMO guidelines if the KRAS 
mutation status was unknown; non-adherent with the 2014 
and 2016 ESMO guidelines if the NRAS mutation status 
was unknown in patients with KRASwt; and non-adherent 
with the 2016 ESMO guidelines if the BRAF mutation 
status was unknown in patients RASwt. All analyses were 
performed using IBM SPSS version 22 (IBM, Armonk, 
New York, United States).
Results
Patient disposition and demographic and clinical 
characteristics
Thirty-three sites recruited 936 patients between Novem-
ber 2016 and April 2017. Of these patients, we excluded 63 
patients, mainly because they had several unresolved que-
ries, thus leading to 873 patients who were included in the 
final analyses.
The patients had a median (interquartile range) age of 
66.0 (59.0–73.0) years, were predominantly women (64%) 
and had ECOG performance status of 0 or 1 (94%). The 
primary tumor was most frequently located in the left-sided 
colon (68%), and the most frequent metastatic site was 
the liver (70%). The baseline characteristics are shown in 
Table 1.
Pattern of treatment with chemotherapy 
and targeted therapies
Overall, at the time of inclusion, 873 patients had received 
one line of treatment, 507 (58%) had received two lines, 
235 (27%) had received three lines, 106 (12%) had received 
four lines, and the remaining patients had received up to 
ten lines. The most frequent chemotherapy schemes were 
the FOLFOX or CAPOX regimens (66%) for first-line 
treatment, FOLFOX, CAPOX or FOLFIRI (70%) for 
second-line treatment, and FOLFOX, FOLFIRI or other 
fluoropyrimidine-based regimens for third- and fourth-line 
(over 60%) treatment (Fig. 1). The most frequent specific 
regimens for the first four lines of chemotherapy are pre-
sented in Table 2. In patients aged 75 years or older, the 
most frequent regimens were as follows: capecitabine (17%), 
CAPOX (16%), and FOLFOX (12%) as first-line treatment; 
irinotecan (13%), capecitabine (10%) and FOLFIRI (10%) 
as second-line treatment; FOLFOX (18%), FOLFIRI (8%), 
irinotecan + cetuximab (8%), capecitabine (8%) and pani-
tumumab (8%) as third-line treatment; and capecitabine 
(32%), FOLFOX (16%) and regorafenib (16%) as fourth-
line treatment.
Sixty percent of patients received targeted therapy as part 
of their first-line treatment, and this proportion increased up 
to approximately 70% of patients as part of the second line 
Table 1  Patient and tumor characteristics
ECOG Eastern Cooperative Oncology Group, IQR interquartile 
range, n number of patients with the parameter, N number of evalu-
able patients for the parameter, SD standard deviation
Characteristic N
Age, 873
 Median (IQR) 66.0 (59.0–73.0)
  > 75 years, n (%) 133 (15.2)
Sex (male), n (%) 873 556 (63.7)
Body mass index, mean (SD) 750 26.5 (4.5)
Time from mCRC diagnosis to inclusion 
in the study (months), median (IQR)
873 16.5 (7.6–30.9)
ECOG performance status, (%) 847
 0 387 (45.7)
 1 410 (48.4)
 ≥ 2 50 (5.9)





Metastatic sites ≥ 3, n (%) 873 80 (9.2)




 Distant lymph nodes 116 (13.3)
 Others 94 (10.8)
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of treatment (Fig. 2). The most frequent targeted therapy, 
regardless of the line of treatment, was bevacizumab, which 
was prescribed in almost 40% of the patients as first-line 
treatment, and this proportion decreased thereafter to 24% as 
fourth-line treatment. Regorafenib was almost not used until 
the third or fourth line, where it was used in approximately 
10% of patients.
Adherence to ESMO guidelines
The KRAS mutation status was unknown in 10–12% of the 
patients according to the ESMO guidelines from 2012, 2014 
and 2016, the NRAS mutation status was known in almost 
100% of the patients with KRASwt according to the ESMO 
guidelines from 2014 and 2016, and the BRAF mutation 
status was unknown in half of the patients who were RASwt 
according to the ESMO guidelines from 2016 (Table 3). 
Between 3 and 14% of the patients received a chemotherapy 
regimen in the first three lines of treatment that was not sup-
ported by the corresponding ESMO guidelines (Table 3).
Discussion
This study, which was conducted in a fairly representative 
sample of patients with mCRC treated in Spain, shows that 
the most frequent chemotherapy regimens for treating this 
condition are FOLFOX, CAPOX, and FOLFIRI, in accord-
ance with the ESMO clinical practice guidelines for the 
management of mCRC [3]. In addition, this study shows that 
the use of targeted therapies for the treatment of metastatic 
disease is not fully consistent with the recommendations 
of the CPGs. In addition, a relevant proportion of patients 
were treated with unknown KRAS, and especially the BRAF, 
mutation statuses.
The demographic and clinical characteristics of our sam-
ple are similar to those of a previous multicenter, multina-
tional study that also included a sample of 649 patients in a 
study conducted in 2009 in Spain [5]. This study used phy-
sician sampling frames based on the distribution of oncol-
ogy-treating providers in each country [5] and therefore, the 
cohort was likely to be representative of the patients of the 
participating country. Thus, this suggests that our sample 
is fairly representative of the patients with mCRC treated 
in Spain.
There was a substantial degree of overlap among the 
most frequent chemotherapy regimens (namely, FOLFOX, 
Fig. 1  Treatment schemes 
from first-line to fourth-line 
chemotherapy in patients with 
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CAPOX and FOLFIRI) administered as first- and second-
line treatment for metastatic disease, and to a lesser extent, 
with those administered as third-line treatment. This 
result suggests that an important proportion of patients 
are retreated with those regimens. Overall, the use of tar-
geted therapies was lower than expected, especially in 
first-line treatment; despite being recommended by clini-
cal practice guidelines [3], only 60% of the patients were 
treated with a targeted therapy. This is an important issue 
since targeted therapies have demonstrated a significant 
survival benefit when administered in combination with 
chemotherapy during first-line and second-line therapy for 
patients with mCRC [21]. This issue is further complicated 
by the fact that in our sample, a substantial proportion of 
the patients were treated without a known RAS mutation 
status, and anti-epidermal growth factor receptor thera-
pies should be restricted to patients with a RASwt status. 
Therefore, delaying the introduction of targeted therapy is 
a suboptimal practice according to the CPGs. The difficul-
ties in accessing some oncologic drugs in several Span-
ish regions, as reflected by SEOM [22], could impact the 
adherence to the recommendations of the CPGs. An analy-
sis by region could clarify this issue, but unfortunately, our 
sample was not large enough for such an analysis.
Regarding the adherence to CPGs by the employed regi-
mens, except for the abovementioned situation with the use 
of targeted therapies, the majority of chemotherapy regi-
mens were among those recommended in the CPGs. How-
ever, the situation with the determination of the RAS and 
BRAF mutation status requires consideration. The benefit 
of determining the RAS and BRAF mutation status for the 
management of mCRC is well known [23] since it allows 
personalization of the treatment approach; similarly, the 
2016 edition of the ESMO clinical practice guidelines rec-
ommend that “RAS testing should be carried out on all 
patients at the time of diagnosis” and that the BRAF muta-
tion status “should be assessed alongside the assessment 
of tumor RAS mutational status for prognostic assessment” 
[3]. In our study, among the patients diagnosed after July 
2016, 12% of these patients had an unknown KRAS muta-
tion statuses and, of those with wild-type RAS, almost 50% 
of the BRAF mutation statuses were unknown. This find-
ing deserves further research to elucidate the barriers that 
preclude the determination of the RAS mutation status, and 
especially the BRAF mutation status.
The main limitations of the study are its retrospec-
tive nature and the use of a nonprobabilistic convenience 
sample. The former limits the quality of the information 
recorded, and the latter limits the generalizability of the 
study; the inclusion of consecutive patients limits the 
potential for selection bias, to a certain extent. In addi-
tion, since written informed consent was required, patients 
with more advanced disease could potentially be less rep-
resented in our sample; thus, approximately half of the 
patients had ECOG performance status of 0. In addition, 
due to the limited information recorded, we only evaluated 
gross markers of adherence to the treatment guidelines.
In conclusion, this study reveals inconsistencies 
regarding adherence to the recommendations of the 
ESMO guidelines for the management of mCRC in Spain. 
Improved adherence to the standard practice described in 
such guidelines for the determination of RAS and BRAF 
mutation statuses and the use of targeted therapies in 
first-line treatment should be considered to guarantee that 
Table 2  Most frequent treatment regimens from first-line to fourth-
line chemotherapy in patients with metastatic colorectal cancer in 
Spain
CAPOX capecitabine/oxaliplatin, FOLFIRI 5-FU/leucovorin/irinote-
can, FOLFOX 5-FU/leucovorin/oxaliplatin, n number of patients with 
the characteristic
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patients can benefit from the best therapeutic approaches 
available.
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